Inv(16)(p13q22) Gene Rearrangement Quantitative MRD Monitor Test
Understanding Minimal Residual Disease Monitoring
The Inv(16)(p13q22) Gene Rearrangement Quantitative MRD Monitor Test represents a breakthrough in leukemia management and monitoring. This advanced molecular diagnostic test specifically targets the inversion 16 chromosomal abnormality, which results in the formation of the CBFB-MYH11 fusion gene – a hallmark genetic alteration found in approximately 5-8% of all acute myeloid leukemia (AML) cases. The ability to detect and quantify minimal residual disease (MRD) has revolutionized how hematologists and oncologists approach leukemia treatment and long-term patient management.
What Does This Test Measure?
This sophisticated test employs real-time PCR technology to precisely detect and measure the presence of the CBFB-MYH11 fusion gene resulting from the inv(16)(p13q22) chromosomal inversion. The test provides:
- Quantitative measurement of leukemia cell burden
- Detection of minimal residual disease at levels as low as 0.01%
- Monitoring of treatment response over time
- Early detection of molecular relapse before clinical symptoms appear
Who Should Consider This Test?
This specialized MRD monitoring test is recommended for patients who have been diagnosed with AML featuring the inv(16)(p13q22) chromosomal abnormality. Specific indications include:
- Patients undergoing treatment for inv(16) positive AML
- Individuals in complete remission requiring ongoing monitoring
- Patients with suspected molecular relapse
- Those undergoing hematopoietic stem cell transplantation
- Individuals participating in clinical trials requiring precise MRD assessment
Clinical Symptoms and Monitoring Needs
Patients with inv(16) AML typically present with symptoms including fatigue, bruising, bleeding tendencies, recurrent infections, and bone pain. However, the true value of MRD monitoring lies in detecting disease recurrence before these clinical symptoms reappear, allowing for earlier intervention and improved outcomes.
Benefits of MRD Monitoring
The Inv(16)(p13q22) Gene Rearrangement Quantitative MRD Monitor Test offers numerous clinical advantages:
- Early Relapse Detection: Identifies molecular relapse months before clinical symptoms appear
- Treatment Guidance: Helps determine when to initiate or modify therapy
- Prognostic Information: Provides valuable data about long-term outcomes
- Personalized Medicine: Enables tailored treatment approaches based on individual response
- Clinical Trial Eligibility: Often required for participation in advanced treatment studies
Understanding Your Test Results
Interpreting MRD test results requires careful consideration by your hematologist or oncologist. Generally, results fall into several categories:
- MRD Negative: No detectable leukemia cells, indicating deep remission
- Low Level MRD: Minimal detectable disease requiring close monitoring
- Increasing MRD: Rising levels suggesting potential relapse
- MRD Positive: Significant detectable disease requiring intervention
Your healthcare provider will interpret these results in the context of your complete clinical picture, including physical examination findings, blood counts, and other laboratory parameters.
Test Pricing and Information
| Test Component | Price (USD) |
|---|---|
| Discount Price | $188 |
| Regular Price | $250 |
| Test Name | Inv(16)(p13q22) Gene Rearrangement Quantitative MRD Monitor Test |
Sample Requirements and Processing
Sample Type: 5 mL (3 mL minimum) whole blood or bone marrow in 1 Lavender Top (EDTA) tube
Shipping Instructions: Ship refrigerated. DO NOT FREEZE.
Required Documentation: Duly filled MRD Requisition form (Form 22) with historical data is mandatory
Turnaround Time: Samples accepted Monday/Thursday by 11 am; Reports available Wednesday/Saturday
Convenient Testing Locations Across USA
GGC DNA has established testing facilities in all major cities throughout the United States, including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our nationwide network ensures that patients and healthcare providers have access to this critical monitoring technology regardless of location.
Take Control of Your Leukemia Management
Early detection of minimal residual disease can significantly impact treatment outcomes and quality of life for patients with inv(16) positive AML. Don’t wait for clinical symptoms to appear – proactive monitoring provides the information needed to make informed treatment decisions.
Ready to schedule your test? Contact us today at +1(267) 388-9828 or book your appointment online. Our specialized team is ready to assist you with this important aspect of your leukemia care journey.
